PDCD1 and neoplasm: While neoAg SLP vax or ICT led to robust rejection of Y1.7LI when initiated on day 7 post-transplant (Figure 1D), a majority of mice displayed tumor outgrowth when treatment with anti-CTLA-4, anti-PD-1, or neoAg SLP vax was initiated on day 12 post-transplant (Figure S11A).